Biochemical remission after transsphenoidal surgery is still unsatisfied in acromegaly patients with macroadenomas, especially with invasive macroadenomas. concerning the impact of preoperative somatostatin analogues (SSAs) on surgical outcomes, previous studies with limited cases reported conflicting results. To assess current evidence of preoperative medical treatment, we performed a systematic review and meta-analysis of comparative studies. A literature search was conducted in pubmed, embase, and the cochrane Library. five randomized controlled trials (Rct) and seven non-Rct comparative studies were included. these studies mainly focused on pituitary macroadenomas though a small number of microadenoma cases were included. for safety, preoperative SSAs were not associated with elevated risks of postoperative complications. With respect to efficacy, the shortterm cure rate was improved by preoperative SSAs, but the long-term cure rate showed no significant improvement. for invasive macroadenomas, the short-term cure rate was also improved, but the long-term results were not evaluable in clinical practice because adjuvant therapy was generally required. in conclusion, preoperative SSAs are safe in patients with acromegaly, and the favorable impact on surgical results is restricted to the short-term cure rate in macroadenomas and invasive macroadenomas. further well-designed Rcts to examine long-term results are awaited to update the finding of this meta-analysis.
Data extraction and outcome of interest. Two researchers (C.Y. & S.J.) extracted data of included studies independently. If there was any disagreement about the eligibility of data, a consensus was reached with the guidance of the senior authors (X.B. & R.W.). The outcomes of interest were short-term and long-term biochemical remission rates in all acromegaly patients (mainly macroadenomas), short-term biochemical remission rates in invasive macroadenomas, and postoperative complication rates. Biochemical remission is measured by one of following criteria: (1) nadir GH <1 ug/L during oral glucose tolerance test (OGTT) and normal levels of IGF-1 adjusted for age and sex; (2) nadir GH <0.4 ug/L during OGTT and normal levels of IGF-1 adjusted for age and sex 7 . Short-term biochemical remission is defined as follows: (1) conducted a biochemical assessment within six months after pituitary surgery; (2) satisfied cure criteria; (3) received no adjuvant therapy before the last biochemical assessment within six months. Long-term biochemical remission is similar as described previously except that the biochemical assessment is conducted after six months postoperatively. If there were several biochemical results during the short/long-term follow-up, the latest result was adopted. The rate was calculated to divide the number of events by the total number of evaluable patients in each group.
Quality assessment and data analysis. The methodological quality of randomized controlled trials (RCT) was assessed using the Cochrane Risk of Bias Tool. The methodological quality of non-RCT comparative studies was assessed using the nine-star Newcastle-Ottawa scale (NOS) 8 . Non-RCT studies with more than six stars and RCTs were considered as high-quality studies in this analysis. The statistical analyses of pooled data were conducted using Review Manager, version 5.3.5 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). The odds ratio to compare dichotomous variables was calculated using the method of the Mantel-Haenszel test. The random-effects model was performed if there was heterogeneity between selected studies; otherwise, the fixed-effects model was performed. Study heterogeneity was determined using the Cochrane Q and I2 statistics. Heterogeneity was considered significant when the p value from Cochrane Q was <0.1 or I 2 >50%. Publication bias was assessed by visually inspecting the funnel plots 9 . www.nature.com/scientificreports www.nature.com/scientificreports/ Quality assessment of included studies. The included studies were all high-quality after careful assessment because they were either RCTs or Non-RCT studies with more than six stars. Among the five RCTs, randomization methods were reported in two studies, and allocation concealment was provided in one study ( Table 2) . Though the clinical outcome assessment of participants was not blinded, the judgment of biochemical remission and postoperative complications was still objective. Therefore, we considered the risk of detection bias as low without blinding of outcome assessment and labeled a star in the part of outcome assessment in NOS. For the seven non-RCT studies, the scores of NOS ranged from seven to eight, indicating high quality ( Table 3 ).
Meta-analysis of short-term biochemical remission.
Nine studies with a total of 688 patients mainly with macroadenomas evaluated the biochemical control within six months after pituitary surgery according to the widely-accepted remission criteria 10, 12, [14] [15] [16] [17] [18] 20, 21 . The meta-analysis was performed using the fix-effects model. The rate of short-term biochemical remission was 162/321 (50.5%) in the SSA group and 129/367 (35.1%) in the non-SSA group. The pooled data showed a significantly higher short-term cure rate in the SSA group than that in the non-SSA group (OR 2.07, 95% CI 1.50-2.87, p < 0.00001) (Fig. 2 ). The I 2 statistic was 45%, demonstrating no significant heterogeneity among the included studies. Further, the ten studies were divided into two groups by short-(n = 3) or long-acting (n = 6) SSAs. A subgroup analysis was performed revealing the same result, which was in favor of preoperative medical treatment (OR 2.06, 95% CI 1.19-3.57, p = 0.01 and OR 2.08, 95% CI 1.40-3.10, p = 0.0003, respectively).
Meta-analysis of long-term biochemical remission.
Five studies with a total of 397 patients mainly with macroadenomas evaluated the biochemical control after over six months postoperatively according to the widely-accepted remission criteria 11, 13, [19] [20] [21] . The meta-analysis was performed using the fix-effects model. The rate of long-term biochemical remission was 133/202 (65.8%) in the SSA group and 107/195 (54.9%) in the non-SSA group. The pooled data showed no significant difference regarding the long-term cure rate between groups (OR 1.49, 95% CI 0.95-2.32, p = 0.08) ( Fig. 3 ). The I 2 statistic was 0%, demonstrating no significant heterogeneity among the included studies.
Meta-analysis of biochemical remission in invasive macroadenomas.
As for invasive macroadenomas, two studies with a total of 88 patients evaluated the biochemical control within six months after pituitary surgery according to the widely-accepted remission criteria 17, 18 . The meta-analysis was performed using the fix-effects model. The rate of short-term biochemical remission was 19/43 (44.2%) in the SSA group and 7/45 (15.6%) in the non-SSA group. The pooled data showed a significantly higher short-term cure rate in the SSA group than that in the non-SSA group (OR 4.33, 95% CI 1.57-11.90, p = 0.005) ( Fig. 4 ). The I 2 statistic was 0%, www.nature.com/scientificreports www.nature.com/scientificreports/ demonstrating no significant heterogeneity among the included studies. There was no publication for data synthesis about the long-term effect because adjuvant treatment was required in these cases, making it impossible to evaluate the real impact of preoperative medical treatment.
Meta-analysis of postoperative complications.
Five studies with a total of 393 patients evaluated the occurrence of postoperative complications 11, 13, 15, 16, 18 . The meta-analysis was performed using the fix-effects model. The rate of postoperative complications was 26/213 (12.2%) in the SSA group and 20/180 (11.1%) in the non-SSA group. The pooled data showed no significant difference regarding postoperative complications between groups (OR 1.14, 95% CI 0.62-2.10, p = 0.67) (Fig. 5 ). The I 2 statistic was 8%, demonstrating no significant heterogeneity among the included studies. publication bias. The funnel plots for all outcomes of interest were overall symmetrical. In each funnel plot, major studies were displayed within the 95% CI, with an even distribution around the vertical, suggesting no obvious publication bias (Figs 6-9). 
Discussion
There is a great debate about the place of preoperative SSAs in acromegaly treatment. Three meta-analyses have been published to summarize the conflicting results of previous studies. Francisco et al. 22 included six controlled studies into a meta-analysis, detecting no significant difference in the cure rate between pretreatment and direct surgery groups (OR 1.62, 95% CI 0.93-2.82). However, when three RCTs were selectively analyzed, a significant effect was revealed to favor the impact of pretreatment on surgical results (OR 3.62, 95% CI 1.88-6.96). However, Francisco et al. 22 neither considered the relation between tumor features and surgical difficulties nor distinguished the short-and long-term cure rate. Nunes et al. 23 performed a meta-analysis based on four RCTs with a total of 248 cases. The result showed that preoperative medical treatment increased the three-month postoperative www.nature.com/scientificreports www.nature.com/scientificreports/ www.nature.com/scientificreports www.nature.com/scientificreports/ biochemical remission rate in GH-secreting pituitary macroadenomas (RR 2.15, 95% CI 1.39-3.33). Nevertheless, the three-month postoperative endocrine assessment was considered unpersuasive because of a carryover effect 5 . To explore more convincing evidence, Zhang et al. 24 conducted another meta-analysis about the long-term effect of preoperative SSAs showing no significant difference (RR 1.03, 95% CI 0.86-1.24).
In our view, tumor invasiveness is the most critical factor to influence the impact of pretreatment. Several recent publications provided further clinical data. Therefore, it is necessary to perform an updated meta-analysis to refine the clinical evidence, with particular attention to invasive macroadenomas.
In this meta-analysis, we found that preoperative treatment of SSAs was associated with the elevated rate of short-term biochemical control in acromegaly, but no improvement was seen in the long-term cure rate. As for the acromegaly caused by invasive macroadenomas, which remained surgical challenges, preoperative treatment of SSAs could significantly improve the short-term cure rate as well. The data of long-term results were not available because radiotherapy, prolonged medical treatment, or both was commonly required in such cases with inoperable residual tumor. For safety, pretreatment exerted no impact on postoperative complications. Our results were consistent with guidelines and previous meta-analyses. Furthermore, this was the first study to report the value of preoperative SSAs in invasive macroadenomas achieving better short-term biochemical remission.
The effect of preoperative SSAs on surgical results was presumed to be multiple in terms of controlling GH, reducing tumor volume, softening tumor consistency, and lowering anesthetic risk. Theoretically speaking, these favorable results of pretreatment should improve the rate of gross total resection and biochemical control. Because the long-term result was unsatisfied, the favorable short-term result was questioned and thought to be due to a carryover effect. The results of unsatisfied long-term biochemical control were mainly from non-RCT studies except for the RCT study with a small sample conducted by Fougner et al. 19 . To elucidate the confusing phenomenon, we proposed the following potential reasons according to our experiences: (1) the included cases were a mixture of microadenomas and macroadenomas, whereas the pretreatment value was limited for microadenomas due to the high cure rate of approximately 90% by transsphenoidal surgery alone; (2) given that development of surgical techniques allows for more delicate resection of large and firm tumors, cavernous sinus invasion is the most significant predictor for surgical outcomes rather than preoperative hormone levels, tumor size and tumor consistency, which were considered as key therapeutic targets of preoperative SSAs. Thus, to clarify the impact of preoperative medical treatment more precisely, we recommend including patients with potentially-resectable invasive macroadenomas into a well-designed RCT.
The strengths of our meta-analysis are considered as follows. First, we made the most comprehensive literature search from three mainstream databases, including Pubmed, Embase, and Cochrane Library in order to www.nature.com/scientificreports www.nature.com/scientificreports/ find the updated clinical evidence. Second, before we performed the meta-analysis, we established a prospective protocol in terms of search strategies, data collection, dispute settlement, and statistical analysis, which was strictly followed in the whole procedure. Third, compared with previous studies, this meta-analysis included the largest number of cases from RCTs and non-RCTs, the qualities of which were relatively high after scale-based evaluation.
However, the present meta-analysis has the following limitations. First, the therapeutic regimen of preoperative somatostatin analogues varied significantly among the included studies. Second, retrospective and prospective cohort studies were included in the final analysis. Randomization is recognized to eliminate the baseline difference between groups. The included retrospective and prospective cohort studies were distinguished from RCTs for not adopting randomization in assigning patients. In three retrospective studies, methods to balance the baseline data were not even reported. Though one or two matching factors were stated in some studies, the inherent drawbacks of the non-RCT design might cause potential selection bias between groups. Third, considering the extensive perioperative use of SSAs, a considerable number of observational studies with negative results might be not reported. The publication bias should not be neglected. Fourth, original data did not show the biochemical control related to individual preoperative imaging features in size and invasiveness, reducing the application value of our results.
conclusion Preoperative medical treatment leads to better short-term cure rates in the acromegalics, but its impact on the long-term results is unclear. In acromegalics with invasive macroadenomas, preoperative medical treatment also shows great efficacy in the short-term cure rate. As for safety, preoperative somatostatin analogues do not increase the risk of postoperative complications. Despite some limitations, the present meta-analysis provides the latest evidence regarding the safety and efficacy of preoperative SSAs.
